Zacks Investment Research upgraded shares of Vical (NASDAQ:VICL) from a sell rating to a hold rating in a report issued on Saturday.
According to Zacks, “Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. “
Several other brokerages have also recently weighed in on VICL. HC Wainwright reaffirmed a buy rating and issued a $6.00 price target on shares of Vical in a research note on Tuesday, November 21st. Ifs Securities reissued an outperform rating on shares of Vical in a research note on Tuesday, August 8th. Finally, ValuEngine cut Vical from a sell rating to a strong sell rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $7.50.
Vical (NASDAQ:VICL) last issued its quarterly earnings results on Monday, October 23rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.02). The firm had revenue of $3.24 million during the quarter, compared to analysts’ expectations of $3.60 million. Vical had a negative return on equity of 29.06% and a negative net margin of 92.13%. research analysts anticipate that Vical will post -1 EPS for the current fiscal year.
In related news, Director Robert C. Merton bought 85,700 shares of the business’s stock in a transaction dated Friday, November 10th. The shares were purchased at an average cost of $1.75 per share, with a total value of $149,975.00. Following the completion of the purchase, the director now owns 95,451 shares in the company, valued at approximately $167,039.25. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 5.88% of the company’s stock.
An institutional investor recently raised its position in Vical stock. Renaissance Technologies LLC raised its stake in Vical Incorporated (NASDAQ:VICL) by 6.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 416,029 shares of the biotechnology company’s stock after acquiring an additional 23,520 shares during the period. Renaissance Technologies LLC’s holdings in Vical were worth $932,000 as of its most recent SEC filing. Institutional investors own 15.46% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Vical (VICL) Raised to “Hold” at Zacks Investment Research” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/12/05/vical-vicl-raised-to-hold-at-zacks-investment-research.html.
Vical Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.